Skip to Content
You are currently on the new version of our website. Access the old version .
  • 2.2
    Impact Factor
  • 3.0
    CiteScore
  • 32 days
    Submission to First Decision
  • 7 days
    Acceptance to Publication

Endocrines

Endocrines is an international, peer-reviewed, open access journal on endocrinology published quarterly online by MDPI.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within ESCI (Web of Science), Scopus, CAPlus / SciFinder, and other databases.
  • Journal Rank: CiteScore - Q2 (Medicine (miscellaneous))
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 31.9 days after submission; acceptance to publication is undertaken in 6.9 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (356)

  • Review
  • Open Access

Background: Obesity is increasingly recognized as a complex neuroimmunometabolic disorder rather than simply a consequence of excessive caloric intake. Chronic low-grade inflammation, oxidative stress, gut microbiota dysbiosis, hypothalamic dysfunction, and alterations in reward-related neural circuits interact to promote persistent weight gain and metabolic deterioration. Despite substantial advances in pharmacological management, achieving long-term obesity control remains challenging because of treatment discontinuation, interindividual variability in treatment response, and the multifactorial nature of the disease. Consequently, there is growing interest in integrative therapeutic strategies that target the interconnected nervous, immune, and metabolic pathways underlying obesity. Methods: A narrative literature review was conducted to examine the neuroimmunometabolic mechanisms underlying obesity and contemporary and emerging therapeutic strategies. The review covered neuroendocrine, inflammatory, metabolic, adipose tissue-related, gut microbiota-related, and therapeutic perspectives. Relevant publications were identified using available biomedical and scientific databases. Publications were screened using the following keywords: “obesity”, “neuroimmunometabolic dysregulation”, “inflammation”, “oxidative stress”, “gut microbiota”, “reward system”, “hypothalamic–pituitary–adrenal axis”, “personalized therapy”, “GLP-1 receptor agonists”, and “emerging therapeutics”. The evidence reviewed included findings from experimental and preclinical studies, as well as clinical studies involving human participants. The review aimed to summarize current knowledge of obesity pathophysiology and established and emerging therapeutic approaches. Results and Conclusions: Current evidence demonstrates that obesity arises from complex interactions involving genetic and epigenetic susceptibility, adipose tissue inflammation, mitochondrial dysfunction, oxidative stress, gut microbiota alterations, HPA axis hyperactivation, and dysregulated dopaminergic and serotonergic signaling. These mechanisms contribute to insulin resistance, impaired appetite regulation, maladaptive eating behaviors, and progressive metabolic dysfunction. Core lifestyle interventions, approved incretin-based pharmacotherapies, and metabolic-bariatric surgery represent established clinical standards. Meanwhile, a range of novel strategies is under investigation. These emerging approaches include anti-inflammatory and nutrigenomic dietary patterns, next-generation probiotics (Akkermansia muciniphila, Hafnia alvei), metabolic adjuvants (melatonin, N-acetylcysteine), mindfulness-based interventions, neuromodulation techniques, and experimental molecular therapies (antisense oligonucleotides, iPSC platforms). These findings support a neuroimmunometabolic model of obesity. However, further longitudinal and translational studies are essential to validate emerging approaches before their routine clinical implementation.

Endocrines

11 November 2026

Neuroimmunometabolic Drivers of Obesity.
  • Review
  • Open Access

Type 2 Diabetes Remission and Long-Term Microvascular Risk: A Critical Review of Longitudinal Evidence

  • Josep Montserrat-Capdevila,
  • Silvia Canivell and
  • Pilar Vaqué Castilla

Background/Objectives: Type 2 diabetes (T2D) remission is increasingly attainable, but its implications for long-term microvascular risk remain uncertain. Methods: We critically appraised longitudinal reports relating achieved remission to subsequent kidney, retinal, neurologic, or composite outcomes, distinguishing temporally separated remission–outcome analyses from supportive glycemic trajectory studies with overlapping ascertainment. Evidence was checked through 5 October 2026, with an additional directly relevant CHIA companion report incorporated during revision. Eight reports were appraised (six principal direct longitudinal reports, one supportive trajectory report, and one contextual retinopathy report); overlapping CHIA populations were identified, while Danish participant overlap remains unverified. Heterogeneous exposures and estimands precluded pooling. Results: Across surgical, lifestyle, primary care and pharmacotherapy settings, several studies associated remission with lower subsequent microvascular risk. In the temporally separated CHIA analysis, remission during the first two years was associated with fewer microvascular complications over the following five years (adjusted HR 0.68, 95% CI 0.62–0.74). In Look AHEAD, remission at any assessed visit was associated with lower high-/very-high-risk chronic kidney disease (HR 0.67, 95% CI 0.52–0.87). Trajectory analyses provide complementary but temporally less secure evidence and should not be equated with medication-free remission. Conclusions: Achieved T2D remission is a potentially informative prognostic state; evidence concerning duration is suggestive but definition- and design-dependent. Neither a causal effect of remission itself nor normalization of prior microvascular risk has been established.

Endocrines

12 November 2026

  • Systematic Review
  • Open Access

Background/Objectives: GLP-1 receptor agonists (GLP-1RAs) and the dual GIP/GLP-1 receptor agonist tirzepatide reduce body weight, but their effects on muscle-related body-composition measures and physical function remain uncertain. We evaluated changes in skeletal muscle mass (SMM), lean mass, and related outcomes and performed a focused meta-analysis of compatible bioelectrical impedance analysis (BIA) cohorts. Methods: PubMed, Embase, and the Cochrane Library were searched for studies published from 2009 through 30 April 2026. Eighteen unique studies reported in 19 publications were included. A post hoc quantitative synthesis pooled five BIA-derived cohorts from four studies in adults with type 2 diabetes using a random-effects model. Results: Nineteen publications describing 18 unique studies (total n = 3541; age range 45.4–76.7 years) were included. The pooled within-group change across compatible BIA cohorts was −0.90 kg (95% CI −1.21 to −0.59; I2 = 57.3%). This estimate does not establish a causal drug effect. DXA and BIA outcomes were synthesized separately because they are not interchangeable. Conclusions: GLP-1RA treatment was accompanied by a small within-group reduction in heterogeneous BIA-derived muscle-mass estimates, but the certainty of this evidence was very low. DXA-derived lean mass, BIA-derived muscle mass, and sarcopenia are not interchangeable outcomes. The available data do not establish a drug-specific loss of contractile muscle or functional decline. Standardized controlled studies incorporating muscle strength and physical performance are required.

Endocrines

11 November 2026

  • Systematic Review
  • Open Access

Background: Near-infrared autofluorescence (NIRAF) imaging has been widely used to identify parathyroid glands, but its impact on postoperative hypoparathyroidism and hypocalcemia remains controversial. This systematic review aims to evaluate the impact of NIRAF on postoperative hypoparathyroidism and hypocalcemia rates compared to conventional thyroid surgery. Methods: This study was conducted in accordance with PRISMA 2020 guidelines. We conducted a systematic search across PubMed, Scopus, and Google Scholar from January 2011 to April 2026. Studies comparing postoperative calcium and parathyroid hormone (PTH) levels, hypoparathyroidism and hypocalcemia rates, parathyroid gland identification rates, and inadvertent parathyroid gland resection rates between NIRAF and conventional surgery were included. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool for randomized controlled studies and the ROBINS-I tool for non-randomized studies (cohort, case–control, before-and-after, and retrospective analyses). We performed a narrative synthesis of the results following the Synthesis Without Meta-analysis (SWiM) reporting guidelines, due to profound diagnostic and threshold heterogeneity across studies. Results: Seventeen studies, including a total of 5163 patients (control = 3397, NIRAF = 1766), with a sample size-weighted mean age of 51.19 years, met the selection criteria and were included in the systematic review. The most common surgical procedure was total thyroidectomy without central neck dissection (ten out of seventeen studies, 58.8%). Regarding the NIRAF device, Fluobeam was the most used among the included studies (64.71%). Across 16 studies evaluating postoperative hypocalcemia, point estimates consistently favored the NIRAF intervention across varying sample sizes, showing a clear directional trend toward reducing transient postoperative hypocalcemia, even when small-sample studies lacked the power to reach statistical significance. Regarding postoperative hypoparathyroidism, the synthesis showed that NIRAF’s clinical utility depends directly on the extent of surgical dissection, providing a major protective effect size when central neck dissection is performed. Conclusions: This systematic review indicates that NIRAF provides protective effects against transient postoperative hypocalcemia and temporary hypoparathyroidism, especially when central neck dissection is performed. NIRAF also significantly increases per-gland parathyroid identification rates and reduces incidental parathyroidectomy. According to this review, NIRAF exerts no significant effects on permanent hypoparathyroidism or permanent hypocalcemia rates. Broad clinical generalization remains limited by the profound heterogeneity in diagnostic thresholds and metrics across the literature.

Endocrines

9 November 2026

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Endocrines - ISSN 2673-396X